AI-generated summary
The authors compared a new subtype of intense pulsed light, rhodamine IPL (r-IPL), with conventional IPL (c-IPL) in forty-five patients with facial telangiectasias. The study aimed to determine whether r-IPL is an effective and safe treatment that could be a first-choice therapy. The abstract does not report the specific outcomes that led to this conclusion.
- Participants
- 45
- Who or what was studied
- Forty-five patients affected by facial telangiectasias
- Limits stated in the abstract
- The abstract does not state the outcome results, comparison group sizes, or follow-up duration.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on tandfonline.com.
Record from PubMed, a service of the National Library of Medicine.
How to read a trial: what to check before relying on this kind of research.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.